MENU
+Compare
AMRX
Stock ticker: NASDAQ
AS OF
Feb 21 closing price
Price
$7.83
Change
-$0.04 (-0.51%)
Capitalization
1.87B

AMRX Amneal Pharmaceuticals Forecast, Technical & Fundamental Analysis

a developer of pharmaceutical products

AMRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for AMRX with price predictions
Feb 21, 2025

Aroon Indicator for AMRX shows an upward move is likely

AMRX's Aroon Indicator triggered a bullish signal on January 30, 2025. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 215 similar instances where the Aroon Indicator showed a similar pattern. In of the 215 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 66 cases where AMRX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where AMRX advanced for three days, in of 273 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for AMRX moved out of overbought territory on January 24, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 34 similar instances where the indicator moved out of overbought territory. In of the 34 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on January 31, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on AMRX as a result. In of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for AMRX turned negative on February 03, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at .

AMRX moved below its 50-day moving average on February 03, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for AMRX crossed bearishly below the 50-day moving average on February 12, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AMRX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

AMRX broke above its upper Bollinger Band on January 23, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock slightly better than average.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. AMRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (94.340) is normal, around the industry mean (59.993). P/E Ratio (90.000) is within average values for comparable stocks, (90.174). AMRX's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.987). Dividend Yield (0.000) settles around the average of (0.122) among similar stocks. P/S Ratio (0.445) is also within normal values, averaging (19.928).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

View a ticker or compare two or three
AMRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

AMRX is expected to report earnings to fall 4.37% to 15 cents per share on February 28

Amneal Pharmaceuticals AMRX Stock Earnings Reports
Q4'24
Est.
$0.15
Q3'24
Beat
by $0.03
Q2'24
Beat
by $0.02
Q1'24
Beat
by $0.05
Q4'23
Beat
by $0.05
The last earnings report on November 08 showed earnings per share of 15 cents, beating the estimate of 12 cents. With 1.31M shares outstanding, the current market capitalization sits at 1.87B.
A.I. Advisor
published General Information

General Information

a developer of pharmaceutical products

Industry PharmaceuticalsOther

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
400 Crossing Boulevard
Phone
+1 908 947-3120
Employees
7700
Web
https://www.amneal.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PISQX13.92-0.04
-0.29%
Columbia Pyrford International Stk Ins 3
DRRCX15.00-0.10
-0.66%
BNY Mellon Global Real Return - C
MSGFX32.93-0.30
-0.90%
Morgan Stanley Inst Global Franchise C
PWDCX9.76-0.13
-1.31%
Donoghue Forlines Dividend C
AULRX80.42-1.93
-2.34%
American Century Ultra® R

AMRX and Stocks

Correlation & Price change

A.I.dvisor tells us that AMRX and HROW have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that AMRX and HROW's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AMRX
1D Price
Change %
AMRX100%
-0.51%
HROW - AMRX
32%
Poorly correlated
-3.92%
CRON - AMRX
32%
Poorly correlated
+1.55%
ORGO - AMRX
32%
Poorly correlated
-5.03%
VTRS - AMRX
30%
Poorly correlated
+1.72%
VRNOF - AMRX
30%
Poorly correlated
N/A
More